These data support the notion that despite possessing a KEAP1 mutation, lung cancer may still be effectively treated with an NRF2 pathway activator and the beneficial anti-tumor effects are likely mediated through cancer cell-independent immune regulation. Here, NFE2L2 is linked to lung carcinoma.